The Food and Drug Administration granted premarket approval to Zoll Medical Corp. to market and distribute its Hospital Wearable Defibrillator.
The device is worn by patients at risk of ventricular tachycardia or ventricular fibrillation during their hospital stays to monitor for irregular heart rhythms.
When the Hospital Wearable Defibrillator detects a life-threatening heart rhythm, it alerts the patient prior to administering a treatment shock. The device is programmed to deliver fibrillation within 60 seconds of the detected irregularity, according to a company news release.
More articles on supply chain:
Viewpoint: Trump is 'crying wolf' on drug price measures
6 must-reads for supply chain leaders this week
Trump nominates Dr. Scott Gottlieb for FDA commissioner: 6 things to know